{
    "organizations": [],
    "uuid": "b4cbf1dde1e4f13dc311dc866cfd901a7733e4ce",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-horizon-pharma-sees-krystexxa-fy-2/brief-horizon-pharma-sees-krystexxa-fy-2018-sales-up-more-than-50-percent-idUSL8N1P330W",
    "ord_in_thread": 0,
    "title": "BRIEF-Horizon Pharma Sees Krystexxa FY 2018 Sales Up More Than 50 Percent",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Horizon Pharma Plc:\n* HORIZON PHARMA SEES KRYSTEXXA FY 2018 SALES UP MORE THAN 50 PERCENT\n* HORIZON PHARMA PLC - INCREASING ITS ESTIMATED PEAK ANNUAL NET SALES EXPECTATIONS FOR EACH MEDICINE TO MORE THAN $750 MILLION\n* HORIZON PHARMA PLC INCREASES PEAK NET SALES GUIDANCE FOR KEY GROWTH DRIVERS AND ANNOUNCES RHEUMATOLOGY AND ORPHAN PIPELINE DEVELOPMENTS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T20:28:00.000+02:00",
    "crawled": "2018-01-09T16:56:55.037+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "horizon",
        "pharma",
        "plc",
        "horizon",
        "pharma",
        "see",
        "krystexxa",
        "fy",
        "sale",
        "percent",
        "horizon",
        "pharma",
        "plc",
        "increasing",
        "estimated",
        "peak",
        "annual",
        "net",
        "sale",
        "expectation",
        "medicine",
        "million",
        "horizon",
        "pharma",
        "plc",
        "increase",
        "peak",
        "net",
        "sale",
        "guidance",
        "key",
        "growth",
        "driver",
        "announces",
        "rheumatology",
        "orphan",
        "pipeline",
        "development",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}